Health Optimization Index
NAD+ (Direct)
- Nick’s assessment
- Experimental
- Research evidence
- D, early evidence
- Attention
- 18.7 / 100▲ Rising this week
BioHarmony score
NAD+ (Direct) is the central redox coenzyme given by IV, injection, sublingual, or intranasal route, and it scores 5.0–5.5/10 because the human evidence is a single 6-hour IV pharmacokinetic study by Grant 2019 with no efficacy trials, while the oral precursors NMN and NR carry stronger data.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
NAD+ (Direct) sits at the bottom of Neutral because it pairs an undisputed, central biology with a nearly empty direct-delivery evidence file and a real IV burden. The molecule matters enormously, but the route being sold, IV drips, subcutaneous injections, sublingual, and intranasal, rests on a single human pharmacokinetic study, per Grant 2019, with no controlled efficacy trial for energy, longevity, cognition, or addiction, and with intact cellular uptake contested, per Kory 2020. If your aim is to raise NAD+, the oral precursors are the better-evidenced, far cheaper route. Direct NAD+ buys a transient drip experience at clinic prices, not a documented outcome. If you want to raise NAD+, the cheapest, best-evidenced move is a precursor capsule, not a thousand-dollar drip. The precursors actually raise blood NAD+ in human trials. Direct NAD+ has one pharmacokinetic study and a transporter that lives inside the mitochondrion, not on the cell surface, which is why intact uptake stays contested. Spend the money where the data is.Kory 2020
✅ Best for: Curious experimenters who want to try the IV infusion ritual and judge it on their own felt response over a session or two. People who already understand that direct NAD+ has one human pharmacokinetic study and no efficacy trials, and who are not expecting a documented longevity or energy result. Anyone who can verify a clinic uses sterile, accurately dosed, properly compounded material rather than grey-market product. Users with money and time to spare who treat it as a low-stakes experiment, not a staple. People drawn to the addiction-recovery framing who accept it rests on testimonials, not controlled trials.
❌ Avoid if: You want an evidence-backed NAD-raising strategy, because the oral precursors carry the human data and direct NAD+ does not. You are cost-sensitive, since infusions run several hundred to over 1000 dollars and must be repeated for any sustained effect. You cannot verify the sterility and sourcing of the product, because compounded IV and research-chemical SubQ material carry contamination and dose-accuracy risk that varies entirely by provider. You react badly to infusions, given the rate-dependent flushing, nausea, and chest tightness. You are chasing the addiction NAD detox claim expecting proof, because no controlled trial supports it.
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →